Latest news with #RTS.S
New Indian Express
6 hours ago
- Health
- New Indian Express
Bharat Biotech to slash malaria vaccine prices by 2028
HYDERABAD: Bharat Biotech International Limited (BBIL) and GSK plc on Wednesday announced a price reduction on the world's first malaria vaccine, RTS.S. The vaccine developed by GSK, PATH and partners will have a price reduction of $5 progressively by 2028. The price reduction is driven by process improvements, expanded production capacity, cost- effective manufacturing. The announcement was made by Bharat Biotech and GSK as a part of Gavi, the Vaccine Alliance, for its next replenishment phase (Gavi 6.0, 2026-2030) by both companies. Dr. Krishna Ella, Executive Chairman of Bharat Biotech International Limited said: 'This pledge to Gavi 6.0 is more than a pricing announcement. It is a commitment to global equity and innovation. Through this historic announcement, we aim to change the course of malaria burden for millions of children and families. For us, this is more than a cooperation, By joining forces with GSK, and working closely with Gavi, and the WHO, we are taking a real step toward closing the gap between vaccine supply and the urgent needs of children at risk of malaria.
United News of India
15 hours ago
- Health
- United News of India
World's first kids' malaria vaccine price to be less than USD 5 by 2028
Hyderabad, June 25 (UNI) Bharat Biotech International Limited (BBIL) and GSK plc, a Global Pharma Company, today announced their commitment to Gavi, the Vaccine Alliance (Gavi), in the continued roll out of the world's first malaria vaccine. Bharat Biotech will be reducing the price of world first malaria vaccine 'RTS.S, developed by GSK, PATH and partners, by more than half, to less than $5 progressively by 2028. This price reduction is driven by process improvements, expanded production capacity, cost- effective manufacturing, and minimal profit margins, Hyderabad based vaccine maker BBIL said in a release here. The announcement forms part of pledges to Gavi for its next replenishment phase (Gavi 6.0, 2026-2030) by both companies. RTS,S was the first malaria vaccine recommended by the World Health Organisation (WHO) in 2021. Since then, GSK has made significant investments to enhance production capacity and efficiency, and to undertake the planned technology transfer to Bharat Biotech. In parallel, Bharat Biotech has invested over $200 million in new, higher- output manufacturing facilities, product development and technology transfers. These enhancements have enabled a phased reduction in the price of the malaria vaccine, starting immediately and fully realised by 2028, when the transfer of production between the two companies is complete. Through Gavi support, RTS,S expected to be rolled out in 12 endemic countries in Africa through routine immunisation programmes by end of 2025 This has only been possible through the critical work that GSK has undertaken with Bharat Biotech, PATH, together with the WHO, implementing countries, MedAccess and Gavi, to help deliver access to life-saving malaria prevention for children in endemic countries in Africa. BBIL Executive Chairman Dr. Krishna Ella, said: "Through this historic announcement, we aim to change the course of malaria burden for millions of children and families. By joining forces with GSK, and working closely with Gavi, and the WHO, we are taking a real step toward closing the gap between vaccine supply and the urgent needs of children at risk of malaria'. In a recent evaluation of impact by the WHO of the Malaria Vaccine Implementation Programme (MVIP) in Ghana, Kenya and Malawi, where over 2 million children received the RTS,S vaccine between 2019 and 2023, the WHO reported a 13 percent reduction in all-cause mortality and a 22 percent reduction in hospitalisations of severe malaria among children age- eligible for vaccination during this period1. When administered seasonally in regions with high malaria transmission, alongside seasonal malaria chemoprevention, the two malaria vaccines recommended by the WHO, have been shown to prevent around 75 percent of malaria episodes. UNI KNR SSP
The Hindu
a day ago
- Health
- The Hindu
Bharat Biotech to begin supplies of GSK's malaria vaccine RTS.S to GAVI in 2026
Bharat Biotech International will start supplying world's first malaria vaccine RTS.S, developed by global biopharma major GSK, to vaccine alliance Gavi from 2026. The supplies form part of pledges by both companies to Gavi for its next replenishment phase (Gavi 6.0, 2026-2030), the Hyderabad-based vaccine maker said on Wednesday, announcing it will also progressively reduce price of the vaccine by more than half to less than $5 by 2028. Process improvements, expanded production capacity, cost-effective manufacturing and minimal profit margins will be factors driving down the price, it said. RTS,S was the first malaria vaccine recommended by the World Health Organization (WHO) in 2021. Technology transfer Since then, GSK has made significant investments to enhance production capacity and efficiency and to undertake the planned technology transfer to Bharat Biotech, which in parallel, invested over $200 million in new, higher-output manufacturing facilities, product development and technology transfers. These enhancements have enabled a phased reduction in the price of the malaria vaccine, starting immediately and fully realised by 2028, when the transfer of production between the two companies is complete, it said. With Gavi's support, 12 endemic countries in Africa will introduce RTS,S through routine immunisation programmes by 2025. 'By joining forces with GSK and working closely with Gavi and the WHO, we are taking a real step toward closing the gap between vaccine supply and the urgent needs of children at risk of malaria,' Bharat Biotech Executive Chairman Krishna Ella said. GSK's Chief Global Health Officer Thomas Breuer said 'We partnered with Bharat Biotech in 2021 with a common goal... Today, we announce GSK's contribution to the long-term price ambition of the world's first malaria vaccine, a key milestone achieved through collaboration with Bharat Biotech and partners from Gavi, PATH and the WHO.' The GSK team has worked hand in hand with Bharat Biotech to transfer the vaccine manufacturing technology, while simultaneously implementing crucial improvements in manufacturing efficiencies, resulting in the pledge to the Gavi replenishment, he said. 'Our ambition is to protect at least 50 million more children across Africa by the end of 2030 and this collaboration between GSK and Bharat Biotech helps put this goal firmly within reach,' Gavi CEO Sania Nishtar said.
